首页> 美国卫生研究院文献>other >Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study
【2h】

Patient Self-Management of Oral Anticoagulation with Vitamin K Antagonists in Everyday Practice: Efficacy and Safety in a Nationwide Long-Term Prospective Cohort Study

机译:日常实践中使用维生素K拮抗剂对患者进行口服抗凝的自我管理:一项全国性长期前瞻性队列研究的功效和安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patient self-management (PSM) of oral anticoagulation is under discussion, because evidence from real-life settings is missing. Using data from a nationwide, prospective cohort study in Switzerland, we assessed overall long-term efficacy and safety of PSM and examined subgroups. Data of 1140 patients (5818.9 patient-years) were analysed and no patient were lost to follow-up. Median follow-up was 4.3 years (range 0.2–12.8 years). Median age at the time of training was 54.2 years (range 18.2–85.2) and 34.6% were women. All-cause mortality was 1.4 per 100 patient-years (95% CI 1.1–1.7) with a higher rate in patients with atrial fibrillation (2.5; 1.6–3.7; p<0.001), patients>50 years of age (2.0; 1.6–2.6; p<0.001), and men (1.6; 1.2–2.1; p = 0.036). The rate of thromboembolic events was 0.4 (0.2–0.6) and independent from indications, sex and age. Major bleeding were observed in 1.1 (0.9–1.5) per 100 patient-years. Efficacy was comparable to standard care and new oral anticoagulants in a network meta-analysis. PSM of properly trained patients is effective and safe in a long-term real-life setting and robust across clinical subgroups. Adoption in various clinical settings, including those with limited access to medical care or rural areas is warranted.
机译:口服抗凝药的患者自我管理(PSM)正在讨论中,因为缺少现实生活中的证据。使用来自瑞士的一项全国性前瞻性队列研究的数据,我们评估了PSM的总体长期疗效和安全性,并检查了亚组。分析了1140例患者(5818.9病人-年)的数据,没有患者失访。中位随访时间为4。3年(范围0。2-12。8年)。接受培训时的中位年龄为54.2岁(范围为18.2-85.2),女性为34.6%。全因死亡率为每100患者年1.4(95%CI 1.1–1.7),房颤患者(2.5; 1.6–3.7; p <0.001),50岁以上患者(2.0; 1.6)更高–2.6; p <0.001)和男性(1.6; 1.2-2.1; p = 0.036)。血栓栓塞事件的发生率为0.4(0.2-0.6),且与适应症,性别和年龄无关。每100个患者-年的大出血发生率为1.1(0.9-1.5)。在网络荟萃分析中,疗效可与标准护理和新型口服抗凝药相媲美。经过适当训练的患者的PSM在长期的现实生活环境中是有效且安全的,并且在各个临床亚组中均很可靠。保证在各种临床环境中采用,包括那些难以获得医疗服务或农村地区的环境。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号